A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders

References

• Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996;8(Suppl 3):497–500
   PubMedGoogle Scholar
• Piccininni M, Di Carlo A, Baldereschi M, et al. Behavioral and psychological symptoms in Alzheimer’s disease: frequency and relationship with duration and severity of the disease. Dementia Geriatr Cogn Disord 2005;19:276–81
   PubMed Web of Science ®Google Scholar
• Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat Rev Drug Discov 2006;5:64–74
   PubMed Web of Science ®Google Scholar
• Banerjee S, Murray J, Foley B, et al. Predictors of institution-alisation in people with dementia. J Neurol Neurosurg Psychiatry 2003;74:1315–6
   PubMed Web of Science ®Google Scholar
• Phillips VL, Diwan S. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. J Am Geriatr Soc 2003;51:188–93
   PubMed Web of Science ®Google Scholar
• Shin IS, Carter M, Masterman D, et al. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry 2005;13:469–74
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Gutterman EM, Sadik K, Papadopoulos G. Health- related quality of life for caregivers of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:209–14
   PubMed Web of Science ®Google Scholar
• Coen RF, O’Boyle CA, Coakley D, Lawlor BA. Individual quality of life factors distinguishing low-burden and high- burden caregivers of dementia patients. Dementia Geriatr Cogn Disord 2002;13:164–70
   PubMed Web of Science ®Google Scholar
• Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002;59:1721–9
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14
   PubMed Web of Science ®Google Scholar
• Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987;48(Suppl):9–15
   Google Scholar
• Cummings JL. The neuropsychiatric inventory: assessing psycho-pathology in dementia patients. Neurology 1997;48:S10–S16
   Web of Science ®Google Scholar
• Wood S, Cummings JL, Hsu MA, et al. The use of the neuro-sychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 2000;8:75–83
   PubMed Web of Science ®Google Scholar
• Mega MS, Masterman DM, O’Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388–93
   Google Scholar
• Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer’s disease: the cholinergic hypothesis revisited. Neurology 1996;47:876–83
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122–6
   PubMed Web of Science ®Google Scholar
• Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 1988;13:371–89
   Google Scholar
• Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer’s disease. Biol Psychiatry 1993;33:536–41
   Google Scholar
• Starkstein SE, Vazquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer’s disease. Neurology 1994;44:2055–9
   PubMed Web of Science ®Google Scholar
• Mega MS, Lee L, Dinov ID, et al. Cerebral correlates of psychotic symptoms in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2000;69:167–71
   PubMed Web of Science ®Google Scholar
• Janowsky DS, Risch SC, Gillin JC. Adrenergic-cholinergic balance and the treatment of affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:297–307
   Google Scholar
• Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996;46:130–5
   PubMed Web of Science ®Google Scholar
• Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer’s disease. Lancet 1985;1:228
   Google Scholar
• Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1–6
   Google Scholar
• Raskind MA, Sadowsky CH, Sigmund WR, et al. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54:836–40
   PubMed Web of Science ®Google Scholar
• Brodaty H, Draper B, Saab D, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 2001;16:504–12
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 2001;16:1043–53
   PubMed Web of Science ®Google Scholar
• Hirono N, Ishii K, Sasaki M, et al. Features of regional cerebral glucose metabolism abnormality in corticobasal degeneration. Dementia Geriatr Cogn Disord 2000;11:139–46
   PubMed Web of Science ®Google Scholar
• Rosler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol 1998;11:211–6
   Google Scholar
• Joffres C, Graham J, Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr 2000;12:403–13
   Google Scholar
• Hatoum HT, Lin SJ, Arcona S, et al. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer’s disease. J Am Med Dir Assoc 2005;6:238–45
   PubMedGoogle Scholar
• Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005;3:137–48
   PubMedGoogle Scholar
• Aupperle PM, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605–12
   PubMed Web of Science ®Google Scholar
• Edwards K, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer’s disease: results of a 52-week open-label study. Clin Drug Invest 2005;25:507–15
   PubMed Web of Science ®Google Scholar
• Suh DC, Arcona S, Thomas SK, et al. Risk of antipsychotic drug use in patients with Alzheimer’s disease treated with rivastigmine. Drugs Aging 2004;21:395–403
   PubMed Web of Science ®Google Scholar
• Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. Br Med J 2005;330:874
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J. Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties. J Geriatr Psychiatry Neurol 1995;8:52–60
   PubMed Web of Science ®Google Scholar
• Narayanan S, Beusterien KM, Thomas SK, et al. Antipsychotic drug use among nursing home residents taking rivastigmine. J Am Med Dir Assoc 2006;7:12–6
   PubMed Web of Science ®Google Scholar
• Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006;60:110–8
   PubMed Web of Science ®Google Scholar
• McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 2005;4:735–42
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361–2
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203–204:141–6
   Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003;18:265–72
   PubMedGoogle Scholar
• Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37–49
   PubMed Web of Science ®Google Scholar
• Potkin SG, Alva G, Gunay I, et al. A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. Drugs Aging 2006;23:241–9
   PubMed Web of Science ®Google Scholar
• Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol 2005;4:771–80
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004;21:931–7
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988;23:271–84
   PubMed Web of Science ®Google Scholar
• Perry EK, Marshall E, Kerwin J, et al. Evidence of a mono-aminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55:1454–6
   PubMed Web of Science ®Google Scholar
• Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann NY Acad Sci 1991;640:197–202
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–6
   PubMed Web of Science ®Google Scholar
• Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199–205
   PubMed Web of Science ®Google Scholar
• Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 2001;16: 184–91
   Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171–4
   Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. New Engl J Med 2004;351:2509–18
   PubMed Web of Science ®Google Scholar
• Scahill L. Diagnosis and evaluation of pervasive developmental disorders. J Clin Psychiatry 2005;66(Suppl 10):19–25
   PubMed Web of Science ®Google Scholar
• Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001;158:1058–66
   Google Scholar
• Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004;19:165–9
   PubMed Web of Science ®Google Scholar
• Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 1980;10:91–103
   PubMed Web of Science ®Google Scholar
• Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiatry Suppl 1999:7–11
   PubMedGoogle Scholar
• Mendelsohn E, Rosenthal M, Bohiri Y, et al. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol 2004;19:319–24
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76
   Google Scholar